MAM
UTHR icon

Meeder Asset Management’s United Therapeutics UTHR Stock Holding History

Meeder Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5M Buy
9,236
+7,733
+515% +$4.36M 0.26% 83
2026
Q1 		$891K Buy
1,503
+240
+19% +$120K 0.05% 178
2025
Q4 		$615K Buy
1,263
+1,252
+11,382% +$583K 0.03% 190
2025
Q3 		$4.61K Sell
11
-1,468
-99% -$494K ﹤0.01% 688
2025
Q2 		$425K Sell
1,479
-673
-31% -$201K 0.03% 187
2025
Q1 		$663K Buy
2,152
+2,134
+11,856% +$731K 0.04% 156
2024
Q4 		$6.35K Hold
18
– – ﹤0.01% 793
2024
Q3 		$6.45K Hold
18
– – ﹤0.01% 704
2024
Q2 		$5.73K Buy
+18
New +$4.76K ﹤0.01% 761
2022
Q4 		– Sell
-275
Closed -$58K – 1954
2022
Q3 		$58K Sell
275
-44
-14% -$9.84K ﹤0.01% 818
2022
Q2 		$75K Sell
319
-59
-16% -$12K ﹤0.01% 783
2022
Q1 		$68K Buy
+378
New +$72K ﹤0.01% 891
2021
Q4 		– Sell
-6,730
Closed -$1.24M – 2296
2021
Q3 		$1.24M Sell
6,730
-192
-3% -$37.8K 0.07% 232
2021
Q2 		$1.24M Sell
6,922
-2,315
-25% -$441K 0.06% 234
2021
Q1 		$1.54M Buy
9,237
+8,949
+3,107% +$1.49M 0.08% 206
2020
Q4 		$44K Sell
288
-7,077
-96% -$929K 0.01% 614
2020
Q3 		$744K Buy
7,365
+327
+5% +$35.9K 0.05% 281
2020
Q2 		$852K Sell
7,038
-70
-1% -$7.88K 0.06% 268
2020
Q1 		$675K Sell
7,108
-98
-1% -$9.31K 0.05% 277
2019
Q4 		$635K Buy
7,206
+2,384
+49% +$210K 0.04% 360
2019
Q3 		$385K Sell
4,822
-594
-11% -$47.8K 0.03% 450
2019
Q2 		$423K Sell
5,416
-1,110
-17% -$104K 0.03% 439
2019
Q1 		$766K Sell
6,526
-2,252
-26% -$262K 0.06% 291
2018
Q4 		$956K Sell
8,778
-439
-5% -$50.9K 0.09% 203
2018
Q3 		$1.18M Sell
9,217
-2,616
-22% -$324K 0.09% 197
2018
Q2 		$1.34M Buy
11,833
+3,442
+41% +$378K 0.12% 166
2018
Q1 		$943K Sell
8,391
-399
-5% -$50.7K 0.09% 209
2017
Q4 		$1.3M Buy
8,790
+1,316
+18% +$167K 0.11% 170
2017
Q3 		$876K Sell
7,474
-2,070
-22% -$264K 0.1% 249
2017
Q2 		$1.24M Sell
9,544
-1,277
-12% -$159K 0.12% 164
2017
Q1 		$1.47M Buy
10,821
+610
+6% +$92.4K 0.13% 157
2016
Q4 		$1.47M Buy
10,211
+2,717
+36% +$347K 0.14% 164
2016
Q3 		$884K Buy
7,494
+7,477
+43,982% +$898K 0.08% 269
2016
Q2 		$2K Hold
17
– – ﹤0.01% 854
2016
Q1 		$2K Buy
+17
New +$2.15K ﹤0.01% 815
2015
Q4 		– Sell
-13,760
Closed -$1.8M – 865
2015
Q3 		$1.8M Buy
13,760
+3,183
+30% +$511K 0.18% 144
2015
Q2 		$1.84M Sell
10,577
-830
-7% -$149K 0.19% 161
2015
Q1 		$1.97M Buy
11,407
+7,172
+169% +$1.09M 0.21% 141
2014
Q4 		$549K Sell
4,235
-36,900
-90% -$4.76M 0.07% 302
2014
Q3 		$5.29M Buy
41,135
+37,070
+912% +$3.82M 0.78% 43
2014
Q2 		$360K Buy
+4,065
New +$391K 0.05% 261

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Meeder Asset Management's UTHR Position: Q2 2026 in Review

Meeder Asset Management increased its United Therapeutics (UTHR) stake by 515% in Q2 2026, buying an estimated $4.36M and bringing the position to 9,236 shares worth $5M. The position accounts for 0.26% of the portfolio, ranked #83.

Meeder Asset Management first reported a position in UTHR in Q2 2014 and has held it in 41 quarters since. The position peaked at $5.29M in Q3 2014. 883 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Meeder Asset Management held 9,236 shares of United Therapeutics worth $5M as of Q2 2026.
  • Meeder Asset Management bought 7,733 United Therapeutics shares in Q2 2026, an estimated $4.36M.
  • United Therapeutics made up 0.26% of Meeder Asset Management's portfolio in Q2 2026, its #83 holding.
  • Meeder Asset Management first reported a position in United Therapeutics in Q2 2014 and has held it in 41 quarters since.
  • Meeder Asset Management's United Therapeutics position peaked at $5.29M in Q3 2014.
  • 883 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.